Trabectedin Increases Toxicity Without Improving PFS and OS in Patients With Meningioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Neuro-oncology 2021 Oct 21;[EPub Ahead of Print], M Preusser, A Silvani, E Le Rhun, R Soffietti, G Lombardi, JM Sepulveda, P Brandal, L Brazil, A Bonneville-Levard, V Lorgis, E Vauleon, J Bromberg, S Erridge, A Cameron, F Lefranc, PM Clement, S Dumont, M Sanson, C Bronnimann, C Balaná, N Thon, J Lewis, MJ Mair, P Sievers, J Furtner, J Pichler, J Bruna, F Ducray, JC Reijneveld, C Mawrin, M Bendszus, C Marosi, V Golfinopoulos, C Coens, T Gorlia, M Weller, F Sahm, W WickFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.